P(185 HER2) AND PS2 PROTEIN OVEREXPRESSION IN BREAST-CANCER SPECIMENS- IMPROVEMENT FOR PREDICTION OF RESPONSE TO ENDOCRINE THERAPY/

Simultaneous analyses of p(185/Her2) and pS2 protein expression in bre ast cancer is discussed to add information about prognosis and respons e to endocrine treatment. In a retrospective study, expression of p(18 5/Her2) and pS2 protein were detected by immunohistochemistry in paraf finembedded, formalin-fixed sections of 219 primary breast cancers. Me dian age was 56.6 years, median follow-up 168 months. Results were cor related with clinical parameters and steroid receptor status. ER was p ositive in 55%, PgR in 54% of the tumors. ER correlated inversely with tumor size, and with tumor grade. pS2 was detected in 54% of the tumo rs, but showed no correlations with other parameters. p(185/Her2) was present in 24% of the tumors and correlated positively with tumor size . pS2 and ER or PgR status correlated (p<0.001). In the sub-group of n egative steroid receptors and positive pS2 a qualitative significant d ifference for p(185/Her2) expression was seen. ER, pS2 and p(185/Her2) status had no prognostic impact on disease-free or overall survival; PgR status correlated with clinical outcome.